Hydroquinone is typically applied to the face, neck, or arms where hyperpigmentation occurs. It should not be used on sensitive areas such as the eyes, mucous membranes, or broken skin, as irritation is more likely.
Visible lightening usually begins after 3 to 4 weeks of consistent use, with optimal improvement seen at 8 to 12 weeks. Results vary depending on the depth of pigmentation and adherence to treatment.
Yes. Using a broad-spectrum sunscreen (SPF 30 or higher) is recommended during hydroquinone therapy to protect treated skin from UV-induced darkening and to reduce irritation.
In the UK, prescription hydroquinone 4 % is commonly supplied in an opaque white or amber tube to protect the product from light. The label will include the concentration, dosage instructions, and the prescribing clinician’s details.
Hydroquinone does not typically cause skin thinning. However, excessive irritation or prolonged use without medical supervision may lead to secondary skin changes, so regular review is essential.
Hydroquinone is a topical agent and is not listed on standard anti-doping prohibited substance tables. Athletes should still disclose all medications to their sport’s medical team.
Stop the application immediately and rinse the area with cool water. Contact a healthcare professional promptly to determine whether the reaction is allergic and whether alternative treatment is needed.
No. Concentrations up to 2 % are sometimes available in cosmetics, but the 4 % prescription strength is classified as a prescription-only medicine (POM) and requires a clinician’s authorization.
Hydroquinone is not intended for tattoo modification. Applying it to tattooed skin may cause uneven lightening and increase the risk of irritation; specialized laser treatments are the preferred approach.
Prescription hydroquinone pricing varies by pharmacy and NHS coverage. Compared with newer agents such as azelaic acid or triple-combo creams, hydroquinone is often less expensive, but exact costs depend on local dispensing fees and insurance status.
Hydroquinone is a topical skin-care agent used to lighten areas of increased pigmentation. It belongs to the class of depigmenting agents and is formulated as a 4 % cream or gel in a tube. In the United Kingdom, hydroquinone 4 % is classified as a prescription-only medicine (POM) and is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The medication works by reducing the production of melanin, the pigment that gives skin its colour, thereby helping to improve the appearance of conditions such as melasma and post-inflammatory hyperpigmentation.
Hydroquinone interferes with the normal synthesis of melanin within melanocytes, the cells responsible for pigment production. It acts primarily as a reversible inhibitor of the enzyme tyrosinase, a key catalyst in the conversion of the amino acid tyrosine to melanin. By lowering tyrosinase activity, hydroquinone reduces the amount of melanin that is formed and deposited in the epidermis. The lightening effect typically becomes noticeable after several weeks of consistent use, as existing pigment is gradually broken down and removed by normal skin turnover. Because the action is topical, systemic absorption is minimal, and the therapeutic effect is largely confined to the area of application.
Hydroquinone 4 % is approved in the UK for the treatment of the following skin conditions:
These indications are supported by clinical guidelines from the British Association of Dermatologists and confirmed by the MHRA’s product licensing. Hydroquinone is generally reserved for adults with a clear diagnosis of these pigmentary disorders, and treatment is usually initiated by a dermatologist or qualified skin-care professional.
These reactions are usually transient and can be managed by reducing the frequency of application or using a gentle moisturizer.
Hydroquinone is applied topically, so systemic drug interactions are uncommon. However, the following considerations are relevant:
If patients are uncertain about any concurrent medication or supplement, they should inform their healthcare provider before initiating hydroquinone therapy.
This article provides educational information about hydroquinone and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
